Fampyra: new option for walking disability in MS

Fampyra (fampridine) is indicated for use in multiple sclerosis to improve walking in patients who have a walking disability (EDSS 4-7).

Recommended dose is twice a day, taken 12 hours apart, without food
Recommended dose is twice a day, taken 12 hours apart, without food
PHARMACOLOGY

Fampridine is a potassium channel blocker. It prolongs channel repolarisation which enhances action potential formation in demyelinated axons, leading to improved neurological function.1

CLINICAL STUDIES

The efficacy of fampridine to improve walking was established in two double-blind studies in which patients with multiple sclerosis were randomised to receive prolonged-release fampridine 10mg twice daily or placebo. Completion of a timed 25-foot walk was used as the primary efficacy endpoint in both studies. Patients who showed a faster walking speed on at least 3 out of 4 occasions, in comparison to their walking speed before treatment, were considered to have responded to treatment.1,2

In one (n=296), 34.8% of patients taking fampridine responded to the treatment, with an average increase in walking speed of 26.3% vs 5.3% on placebo (p<0.001). The other (n=237) showed similar results with 42.9% responding to treatment and an increase in walking speed of 25.3% vs 7.8% (p<0.001).1-3

Treatment should be initiated and supervised by a specialist doctor experienced in the management of multiple sclerosis. Treatment should be limited to two weeks by which time any clinical benefits should have been identified. A timed walking test should be used to evaluate improvement after two weeks. If no benefits are observed, Fampyra should be discontinued.1

REFERENCES

1.    
2.   
3.   

View Fampyra drug record

Further information: Biogen Idec
Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

More from intelog

Ranitidine in short supply after contamination fears prompt precautionary recall

Ranitidine in short supply after contamination fears prompt precautionary recall

GPs have reported shortages of ranitidine following...

Drug shortages - live tracker

Drug shortages - live tracker

Added: Alzhok and ranitidine oral soln.
Use our...

Excessive steroid dosing highlighted in inflammatory bowel disease

Excessive steroid dosing highlighted in inflammatory bowel disease

Some patients with Crohn's disease or ulcerative colitis...

Blood Glucose Testing Strips and Meters

Blood Glucose Testing Strips and Meters

Compatible test strips for blood glucose meters.